Update on Medication- Related Osteonecrosis of the Jaw
Bone health and maintenance of bone integrity are important concerns during comprehensive cancer care and management of osteoporosis. Bisphosphonates are antiresorptive medications widely used for the prevention and treatment of osteoporosis and skeletal complications associated with metastatic cancer and multiple myeloma. Medication-related osteonecrosis of the jaw (MRONJ) related to antiresorptive therapy and chemotherapy is a condition that has created numerous dilemmas in patient management and may have a broad health impact. This case-based presentation will review evidence-based data that has led to paradigm shifts for pathogenesis and innovative strategies for risk assessment, prevention and management of MRONJ.
1. Strategies for diagnosis of MRONJ related to clinical presentation, imaging and differential diagnosis.
2. Risk assessment for dental treatment: What works and what doesn’t.
3. Pathogenesis: What we know today and how this may impact clinical decisions.
4. Strategies for improving oral health via dentoalveolar surgery, restorative dentistry and implant surgery.
5. Alternative management options for patients with MRONJ.
3 CE provided by Calderon Institute
November 15, 2016 6:30 PM - 9:30 PMEastern Time
LaGuardia Plaza Hotel104-04 Ditmars Blvd.East Elmhurst, NY 11369
Limited Seats - Reserve Now!
Call: 855.472.5050 or
Cvent Online Event Registration Software | Copyright © 2000-2016 Cvent, Inc. All rights reserved.